Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Chief information officer

- PMLiVE

Merck’s adult-specific pneumococcal vaccine shows promise in late-stage study

There are more than 100 types of pneumococcal bacteria, which can affect adults differently than children

- PMLiVE

How to successfully manage change and enable digital transformation within pharma

Change is an essential aspect of any business, and learning to manage it effectively will be key for long-term success. Getting your team on board with change and digital transformation...

Graphite Digital

- PMLiVE

Merck acquires Abceutics in deal worth $208m to improve safety of ADCs

As part of the deal, Merck will gain access to the start-up’s payload selectivity enhancer technology

- PMLiVE

Merck’s Keytruda regimen granted EC approval for expanded lung cancer use

The approval represents the sixth lung cancer indication for the anti-PD-1 therapy in Europe

- PMLiVE

Merck’s Winrevair granted FDA approval to treat pulmonary arterial hypertension in adults

The rare blood vessel disorder affects approximately 500 to 1,000 people in the US every year

- PMLiVE

Merck’s pneumococcal vaccine candidate for adults shows promise in late-stage studies

V116 is designed to address the strains responsible for the majority of adult pneumococcal disease

- PMLiVE

Merck presents positive phase 3 data for Keytruda plus CRT in advanced cervical cancer

According to WHO, cervical cancer is the fourth most common cancer in women globally

- PMLiVE

Ensuring a seamless transition from design to development: Strategies for successful collaboration

When designing digital products and services, the process of transitioning from design to development plays a critical role in bringing concepts to life. Our Design Lead, Edward Hart, explains why...

Graphite Digital

- PMLiVE

Is your pharma brand site meeting HCP expectations? Our checklist of common mistakes

Here’s 8 things you can check your brand site for today to ensure it’s delivering, and engaging HCPs.

Graphite Digital

- PMLiVE

Merck shares positive results for Keytruda in phase 3 bladder cancer study

About 83,000 people in the US will be diagnosed with bladder cancer in 2024

- PMLiVE

Merck shares positive results for Keytruda in phase 3 kidney cancer study

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Merck expands cancer immunotherapy pipeline with $680m Harpoon acquisition

The deal includes a T-cell engager for lung cancer and neuroendocrine tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links